A First in Fibromyalgia Treatment After 15 Years: FDA Approves Tonmya
In this article
New Hope for Fibromyalgia From the FDA
The FDA (US Food and Drug Administration)approved a fibromyalgia treatment containing cyclobenzaprine hydrochloride —the sublingual tablet Tonmya, on August 15, 2025 . This is the first new FDA-licensed fibromyalgia treatment in over 15 years , making it a notable approval and an important milestone for the medical community.
Fibromyalgiais among the most common chronic pain syndromes. It affects more than 10 million people in the US alone , approximately 80% of whom are women. Beyond pain, fatigue, sleep disturbance, and cognitive difficulties create an invisible disability. This approval therefore offers the possibility of improved quality of life for millions.
💡 Brief Facts About Fibromyalgia
- Symptoms: Widespread muscle and joint pain, sleep disturbance, severe fatigue, difficulty concentrating ("brain fog").
- Epidemiology: Affects approximately 2–4% of the population worldwide, more commonly women.
- Pathophysiology: Although the exact cause is unknown, increased sensitivity to pain signals in the central nervous system and disrupted sleep cycles are implicated.
- Treatment: There is no single miracle treatment. Medicines, exercise, sleep hygiene, stress management, and psychosocial support are combined.
💊 The Approved Drug: Tonmya
- Active ingredient: Cyclobenzaprine hydrochloride (sublingual tablet, placed under the tongue)
- Brand: Tonmya (Tonix Pharmaceuticals)
- Administration: Placed under the tongue once daily, just before bedtime.
- Goal: Correcting nonrestorative sleep, a key trigger of fibromyalgia pain, fatigue, and brain fog .
Clinical Trial Findings
Tonmya was evaluated in three major phase 3 trials: RELIEF, RESILIENT and RALLY.
1. RELIEF and RESILIENT
- Total patients: ~1000
- Design: Double-blind, randomized, placebo-controlled
- Duration: 14 weeks
- Results:
- Daily pain scores decreased significantly versus placebo.
- A substantial proportion of Tonmya recipients achieved a pain reduction of 30% or more .
- At 3 months, clinically meaningful benefit was observed.
- Publication: RESILIENT results were published on July 8, 2025, in Pain Medicine .
2. RALLY
- Patients: More than 500
- Findings: Treatment effects were greater with Tonmya than placebo, but statistical significance was not reached.
⚙️ Mechanism: Cyclobenzaprine and Sleep Regulation
Tonmya is structurally similar to tricyclic antidepressants but is used not as an antidepressant, but as a low-dose muscle relaxant . Its key feature is strengthening deep sleep (slow-wave sleep) , which is often disrupted in fibromyalgia.
- Central action: Acts on the brainstem's locus coeruleus and, at the spinal level, serotonin (5-HT2) receptors .
- Sleep architecture: Restores deep sleep, strengthening its restorative effects.
- Pain perception: Better-quality sleep improves central nervous system pain-processing mechanisms.
💡 In brief: Tonmya does not directly suppress pain signals like a conventional painkiller; an indirect mechanism through sleep relieves fibromyalgia symptoms.
Safety Profile
Across all phase 3 studies, Tonmya was generally well tolerated. No serious adverse effects were reported. The most common effects were mild-to-moderate:
- Local discomfort from sublingual administration
- Dry mouth
- Mouth ulcers
- Fatigue
- Drowsiness
Conclusion and Expectations
As the first new nonopioid, centrally acting option, Tonmya represents one of the most important fibromyalgia developments in 15 years. It was expected to reach the market in the final quarter of 2025 .
This development may add a new dimension to fibromyalgia management, particularly for symptoms associated with sleep disturbance . It is expected to become a valuable tool for improving daily quality of life.
Sources
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.